GO
Loading...

Pharmaceuticals

More

  • Arrowhead buys Novartis' RNAi portfolio Thursday, 5 Mar 2015 | 7:34 AM ET

    March 5- Arrowhead Research Corp said it acquired Novartis AG's RNAi assets to fortify its position in the field of gene therapy that aims to wipe out disease-causing proteins. Novartis is eligible to receive $25 million in Arrowhead shares within 30 days, which would make it the second-largest shareholder based on Arrowhead's market value on Wednesday.

  • AbbVie will spend about $21 billion to buy fellow drugmaker Pharmacyclics and add another major revenue producer to a portfolio that already includes the world's top-selling drug. AbbVie executives told analysts on Thursday that their company could reap more than $7 million in annual sales from Imbruvica in a few years. While AbbVie touted the potential...

  • AbbVie will pay $261.25 per share in cash and stock, a 13 percent premium to Pharmacyclics stock's closing price on Wednesday on the Nasdaq. Pharmacyclics stockholders can elect cash, AbbVie stock or a combination, subject to proration, the company said in a statement. "Imbruvica is not only complementary to AbbVie's oncology pipeline, it has demonstrated...

  • AbbVie to buy Pharmacyclics in $21 billion deal Wednesday, 4 Mar 2015 | 10:59 PM ET

    March 4- AbbVie Inc said it will buy cancer drug company Pharmacyclics Inc in a $21 billion deal.

  • Nikkei edges up, BOJ's ETF buying helps sentiment Wednesday, 4 Mar 2015 | 9:28 PM ET

    *Rakuten falls after Goldman cuts rating. TOKYO, March 5- Japan's Nikkei share average edged up on Thursday after the central bank bought more exchange-traded funds, but gains were limited by investor caution ahead of U.S. jobs data on Friday. Ono Pharmaceutical Co, which co-develops cancer treatment drug Opdivo with Bristol Myers Squibb, jumped 8 percent after...

  • March 4- Johnson& Johnson is close to buying cancer drug maker Pharmacyclics Inc in the coming days, the Financial Times reported, citing sources. A bid from J&J is expected to value Pharmacyclics near its $17.5 billion market value or at a premium, FT said on Wednesday, citing people familiar with the matter. Bloomberg reported last month, citing sources, that...

  • Technology is raising a high bar for high-end mixology Wednesday, 4 Mar 2015 | 1:42 PM ET

    Take the "Highlander," a cocktail offered at Barmini in Washington, D.C. The drink is a combination of bartender Juan Coronado's favorite highland ingredients, scotch and mezcal from Oaxaca, combined with a touch of simple syrup and served in a glass with a floating cloud of creme de cocoa, rosemary, citrus peels and dry ice. "It's quite amazing to see this floating...

  • *Actavis launches $21 billion bond deal. *Exxon Mobil to sell $7 billion in debt. Pharmaceutical company Actavis Plc launched a $21 billion corporate bond deal, the second-largest on record, according to Thomson Reuters unit IFR.

  • TORONTO, March 3- Canada's stock market regulator said on Tuesday it will amend or cancel trades in the shares of tiny pharmaceutical company Immunovaccine Inc after they surged on Friday following a hoax. The stock jumped more than 30 percent to 89 Canadian cents after an unauthorized statement said Immunovaccine had entered a partnership with a much larger...

  • FDA warning: men's testosterone drugs overused Tuesday, 3 Mar 2015 | 12:10 PM ET

    Additionally, the FDA cautioned that the drugs may increase the risk of heart attack, stroke and other cardiovascular problems. Drugmakers must add information about that potential risk to their prescribing labels and conduct a long-term study to further examine the issue, the FDA said. The FDA action follows years of industry marketing for new gels, patches...

  • *Actavis launches $21 bln bond deal. *Exxon Mobil to sell $7 bln in debt. Pharmaceutical company Actavis Plc launched a $21 billion corporate bond deal, the second-largest on record according to Thomson Reuters unit IFR.

  • Cramer's Stop Trading: Goldman unkind to Mankind  Tuesday, 3 Mar 2015 | 9:54 AM ET

    CNBC's Jim Cramer explains why he is watching Mankind.

  • March 2- U.S. generic drug maker Mylan Inc is still on the prowl for more deals, after completing the multibillion-dollar acquisition of some of Abbott Laboratories' non-U.S. businesses just last week. The company forecast 2015 revenue of $9.6 billion to $10.1 billion and adjusted earnings of $4 to $4.30 per share. The company said it still expects to launch a...

  • March 2- Generic and specialty drugmaker Mylan Inc reported a rise in quarterly profit and revenue, driven mainly by strong demand for its generics in North America. Net profit attributable to the company's common shareholders rose to $189.2 million, or 47 cents per share, in the fourth quarter ended Dec. 31, from $180.2 million, or 45 cents per share, a year earlier.

  • NEW YORK, March 2- U.S. Pharmaceutical company Actavis on Monday was marketing bonds that are expected to total $22 billion, the second largest amount ever sold by a corporate borrower. "Corporate deals are weighing on the market, and we've heard of some allocation out of bonds into equities," said Sean Murphy, a Treasuries trader at Societe Generale in New York.

  • Biotech drugmaker Amgen Inc.' s blood cancer drug Kyprolis doubled the time it kept the disease from worsening, compared with rival drug Velcade, according to the company. Amgen, based in Thousand Oaks, California, on Sunday released interim results from its study. The Amgen- funded study, known by the acronym ENDEAVOR, included 929 patients who had relapsed after...

  • LONDON, March 2- GlaxoSmithKline and Novartis said on Monday they had completed a series of asset swaps worth more than $20 billion that will reshape both drugmakers. GSK is forming a consumer health joint venture with Novartis, while at the same time buying the Swiss company's vaccines business and divesting its cancer drugs portfolio to Novartis.

  • Dublin- based Actavis Plc holds the commercial license for the product, but the marketing application was submitted by non-profit pharmaceutical company Medicines360, which holds the U.S. public sector clinic rights. The companies expect the device, which also helps to check heavy menstrual bleeding, to be available in the United States by the second quarter...

  • Actavis' contraceptive device wins U.S. FDA approval Friday, 27 Feb 2015 | 8:10 AM ET

    Feb 27- The U.S. Food and Drug Administration said on Friday it approved a hormonal contraceptive device, providing American women another reversible contraceptive choice as effective as sterilization. Actavis Plc holds the commercial license to the device, the marketing application of which was submitted by non-profit pharmaceutical company...

  • Why antibiotics need innovation: Ezekiel Emanuel  Friday, 27 Feb 2015 | 7:18 AM ET

    We are losing the battle against bacteria, says Dr. Ezekiel Emanuel, University of Pennsylvania Medical Ethics Department, discussing the need to incentivize the development of new antibiotics.